「CGMP」の共起表現一覧(1語右で並び替え)
該当件数 : 33件
| levels of cyclic guanosine 3'5'-monophosphate ( | cGMP), an action that causes the vasorelaxant effect |
| activity, thereby lowering the concentration of | cGMP, an intracellular second-messenger molecule. |
| and Technical Issues Related to Pharmaceutical | CGMP, and they have 30 calendar days to do so. |
| of physiological processes mediated by cAMP or | cGMP by inhibition of their degradation by PDE. |
| nucleotide phosphodiesterases (PDE) can degrade | cGMP by hydrolyzing cGMP into 5'-GMP. |
| Once formed, | cGMP can be degraded by phosphodiesterases, which th |
| Northwestern Memorial Hospital | cGMP Cell Therapy Lab: Chicago, IL |
| CGMP charges involving active pharmaceutical ingredi | |
| Decrease in | cGMP concentration leads to the closure of cGMP-regu |
| PKG-Iβ is activated at ~10-fold higher | cGMP concentrations than PKG-Iα. |
| d in Plantation, Florida, is a fully integrated | cGMP Contract Manufacturing Organization or (CMO) of |
| ubstance had been manufactured by Lonza, in its | cGMP facilities in Slough, UK. |
| "Biochemistry of Soluble Guanulate Cyclase", | CGMP: Generators, Effectors and Therapeutic Implicat |
| hosphate (GMP), cyclic guanosine monophosphate ( | cGMP), guanosine diphosphate (GDP), and guanosine tr |
| cluding: a current good manufacturing practice ( | cGMP) hot cell laboratory, advanced high-resolution |
| f cyclic nucleotide PDEs that catalyze cAMP and | cGMP hydrolysis. |
| (PDE5), which is responsible for degradation of | cGMP in the corpus cavernosum. |
| in increases the intracellular concentration of | cGMP, induces chloride secretion and decreases intes |
| Like cAMP, | cGMP is known to regulate many cellular proteins, su |
| Like cAMP, | cGMP is an important second messenger that internali |
| In smooth muscle, | cGMP is the signal for relaxation, and this it is co |
| cGMP is also seen to mediate the switching on of the | |
| SGC generates | cGMP, leading to a sequence of chemical activations |
| McGuff Pharmaceuticals, Inc. is an FDA reviewed | cGMP manufacturer of sterile injectable drugs. |
| tified as a fourth subunit of rod cell-specific | cGMP phosphodiesterase (PDE) (EC 3.1.4.35). |
| s an enzyme cascade of G-proteins (transducin), | cGMP phosphodiesterase, closure of a cation channel |
| ic guanosine 3',5'-phosphate phosphodiesterase, | cGMP phosphodiesterase, cGMP-PDE, and cyclic guanosi |
| ylate Cyclase then proceeds to transform GTP to | cGMP, replenishing the cell's cGMP levels and thus r |
| lated TSP1-mediated vascular cell responses and | cGMP signaling. |
| ypically activated by nitric oxide to stimulate | cGMP synthesis. |
| Guanylate cyclase (GC), catalyzes | cGMP synthesis. |
| Step 5: Guanylyl cyclase (GC) synthesizes | cGMP, the second messenger in the phototransduction |
| cGMP will then stimulate cGMP-dependent protein kina | |
こんにちは ゲスト さん
|
ログイン |
Weblio会員(無料)になると
|
こんにちは ゲスト さん
|
ログイン |
Weblio会員(無料)になると
|